Suppr超能文献

炎症性肠病自然史中的关键步骤。

Crucial steps in the natural history of inflammatory bowel disease.

机构信息

Gastroenterology Unit, Department of Internal Medicine and Public Health, University of L'Aquila, L'Aquila, Italy.

出版信息

World J Gastroenterol. 2012 Aug 7;18(29):3790-9. doi: 10.3748/wjg.v18.i29.3790.

Abstract

Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic, progressive and disabling disorders. Over the last few decades, new therapeutic approaches have been introduced which have led not only to a reduction in the mortality rate but also offered the possibility of a favorable modification in the natural history of IBD. The identification of clinical, genetic and serological prognostic factors has permitted a better stratification of the disease, thus allowing the opportunity to indicate the most appropriate therapy. Early treatment with immunosuppressive drugs and biologics has offered the opportunity to change, at least in the short term, the course of the disease by reducing, in a subset of patients with IBD, hospitalization and the need for surgery. In this review, the crucial steps in the natural history of both UC and CD will be discussed, as well as the factors that may change their clinical course. The methodological requirements for high quality studies on the course and prognosis of IBD, the true impact of environmental and dietary factors on the clinical course of IBD, the clinical, serological and genetic predictors of the IBD course (in particular, which of these are relevant and appropriate for use in clinical practice), the impact of the various forms of medical treatment on the IBD complication rate, the role of surgery for IBD in the biologic era, the true magnitude of risk of colorectal cancer associated with IBD, as well as the mortality rate related to IBD will be stressed; all topics that are extensively discussed in separate reviews included in this issue of World Journal of Gastroenterology.

摘要

炎症性肠病(IBD),包括溃疡性结肠炎(UC)和克罗恩病(CD),是慢性、进行性和致残性疾病。在过去的几十年中,已经引入了新的治疗方法,不仅降低了死亡率,而且还提供了改善 IBD 自然史的可能性。临床、遗传和血清学预后因素的确定允许对疾病进行更好的分层,从而有机会指出最合适的治疗方法。早期使用免疫抑制剂和生物制剂治疗为至少在短期内改变疾病进程提供了机会,通过减少一部分 IBD 患者的住院和手术需求。在这篇综述中,将讨论 UC 和 CD 的自然史中的关键步骤,以及可能改变其临床病程的因素。将强调高质量研究在 IBD 病程和预后方面的方法学要求、环境和饮食因素对 IBD 临床病程的真正影响、IBD 病程的临床、血清学和遗传预测因素(特别是这些因素中哪些与临床实践相关且适用)、各种形式的医学治疗对 IBD 并发症发生率的影响、生物时代 IBD 手术的作用、IBD 相关结直肠癌的真正风险程度以及与 IBD 相关的死亡率;所有这些主题都在本卷《世界胃肠病学杂志》中的单独综述中进行了广泛讨论。

相似文献

1
Crucial steps in the natural history of inflammatory bowel disease.
World J Gastroenterol. 2012 Aug 7;18(29):3790-9. doi: 10.3748/wjg.v18.i29.3790.
2
Clinical, serological and genetic predictors of inflammatory bowel disease course.
World J Gastroenterol. 2012 Aug 7;18(29):3806-13. doi: 10.3748/wjg.v18.i29.3806.
3
Impact of medical therapies on inflammatory bowel disease complication rate.
World J Gastroenterol. 2012 Aug 7;18(29):3823-7. doi: 10.3748/wjg.v18.i29.3823.
5
The epidemiology of inflammatory bowel disease.
Scand J Gastroenterol. 2015 Aug;50(8):942-51. doi: 10.3109/00365521.2015.1014407. Epub 2015 Feb 17.
6
Inflammatory bowel disease. Part I: Nature and pathogenesis.
Dis Mon. 1991 Oct;37(10):605-66. doi: 10.1016/0011-5029(91)90024-6.
8
Current therapeutic approaches in inflammatory bowel disease.
Curr Pharm Des. 2010;16(33):3668-83. doi: 10.2174/138161210794079155.
9
Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?
World J Gastroenterol. 2012 Aug 7;18(29):3839-48. doi: 10.3748/wjg.v18.i29.3839.
10
Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD.
Gastroenterology. 2021 Apr;160(5):1452-1460.e21. doi: 10.1053/j.gastro.2020.10.065. Epub 2021 Jan 6.

引用本文的文献

1
Early subclinical stages of the inflammatory bowel diseases: insights from human and animal studies.
Am J Physiol Gastrointest Liver Physiol. 2025 Jan 1;328(1):G17-G31. doi: 10.1152/ajpgi.00252.2024. Epub 2024 Nov 5.
2
Progression of Crohn's Disease in Newly Diagnosed Patients: Results from an Observational Study Using US Claims Data.
Dig Dis Sci. 2024 Nov;69(11):4167-4177. doi: 10.1007/s10620-024-08591-7. Epub 2024 Oct 22.
3
Role of pH-sensing receptors in colitis.
Pflugers Arch. 2024 Apr;476(4):611-622. doi: 10.1007/s00424-024-02943-y. Epub 2024 Mar 22.
4
Pterostilbene: a potential therapeutic agent for fibrotic diseases.
Inflammopharmacology. 2024 Apr;32(2):975-989. doi: 10.1007/s10787-024-01440-z. Epub 2024 Mar 1.
5
The inflammatory bowel disease care manager: Italian state of the art.
Ann Gastroenterol. 2024 Jan-Feb;37(1):37-45. doi: 10.20524/aog.2023.0852. Epub 2023 Dec 23.
7
Identification of hub genes and immune infiltration in ulcerative colitis using bioinformatics.
Sci Rep. 2023 Apr 13;13(1):6039. doi: 10.1038/s41598-023-33292-y.
8
Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center.
Patient Prefer Adherence. 2023 Mar 23;17:807-816. doi: 10.2147/PPA.S390349. eCollection 2023.
9
Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn's Disease.
J Clin Med. 2022 Nov 28;11(23):7020. doi: 10.3390/jcm11237020.
10
Trends in inflammatory bowel disease infections and vaccinations in the past four decades: A high-level text mining analysis of PubMed publications.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2065814. doi: 10.1080/21645515.2022.2065814. Epub 2022 Apr 26.

本文引用的文献

1
Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?
World J Gastroenterol. 2012 Aug 7;18(29):3839-48. doi: 10.3748/wjg.v18.i29.3839.
2
Role of surgery in severe ulcerative colitis in the era of medical rescue therapy.
World J Gastroenterol. 2012 Aug 7;18(29):3833-8. doi: 10.3748/wjg.v18.i29.3833.
3
Surgery for Crohn's disease in the era of biologicals: a reduced need or delayed verdict?
World J Gastroenterol. 2012 Aug 7;18(29):3828-32. doi: 10.3748/wjg.v18.i29.3828.
4
Impact of medical therapies on inflammatory bowel disease complication rate.
World J Gastroenterol. 2012 Aug 7;18(29):3823-7. doi: 10.3748/wjg.v18.i29.3823.
5
Impact of environmental and dietary factors on the course of inflammatory bowel disease.
World J Gastroenterol. 2012 Aug 7;18(29):3814-22. doi: 10.3748/wjg.v18.i29.3814.
6
Clinical, serological and genetic predictors of inflammatory bowel disease course.
World J Gastroenterol. 2012 Aug 7;18(29):3806-13. doi: 10.3748/wjg.v18.i29.3806.
7
Methodology for high-quality studies on course and prognosis of inflammatory bowel disease.
World J Gastroenterol. 2012 Aug 7;18(29):3800-5. doi: 10.3748/wjg.v18.i29.3800.
8
Treatment of inflammatory bowel diseases: to heal the wound or to heal the sick?
J Crohns Colitis. 2012 Jun;6(5):621-5. doi: 10.1016/j.crohns.2012.02.009. Epub 2012 Mar 15.
9
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Gastroenterology. 2012 May;142(5):1102-1111.e2. doi: 10.1053/j.gastro.2012.01.035. Epub 2012 Feb 8.
10
Clostridium difficile Infection and Inflammatory Bowel Disease: A Review.
Gastroenterol Res Pract. 2011;2011:136064. doi: 10.1155/2011/136064. Epub 2011 Sep 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验